North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-01-05 Diabetic neuropathy
| Duloxetine |
|
First Choice
|
30mg & 60mg gastro-resistant capsules
Do not prescribe 90mg & 120mg gastro-resistant capsules |
|
| Gabapentin |
|
Third Choice
|
|
 MHRA Drug Safety Update (Oct 2017): Gabapentin (Neurontin): risk of severe respiratory depression |
|
|
unlicensed indication.| Tramadol |
|
Formulary
|
|
|
MHRA Drug Safety Update (June 2024): Warfarin: be alert to the risk of drug interactions with tramadol |
|
Links
- MHRA Drug Safety Update (Apr 2022): Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update (Feb 2021): Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA Drug Safety Update (Jan 2026): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
- MHRA Drug Safety Update (June 2024): Warfarin: be alert to the risk of drug interactions with tramadol
- MHRA Drug Safety Update (Oct 2017): Gabapentin (Neurontin): risk of severe respiratory depression
- NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings
- NICE NG 28: Type 2 diabetes in adults: management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- North East and North Cumbria ICS - Medication Management of Type 2 Diabetes in Adults Guidelines
- NTAG Endocrine System Recommendations